Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...

Final results from a landmark EORTC randomized trial with more than 20 years of follow-up show that irradiation of the ...

ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune diseases, today announced results from a systematic ...

The developer of a non-invasive blood-based assay, BCAL hopes to enter the US market by the quicker lab-developed test route.

The group is aiming to raise £900 for charity ...

A new DNA test could help screen whether patients require the treatment or not, according to a new international trial.

Final results from a landmark EORTC randomised trial with more than 20 years of follow-up show that irradiation of ...

Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial ...

Broadcaster James Valentine was offered two different treatments for his cancer, so he chose the one that let him keep doing ...

Deb Hipp is a freelance health and medical writer and editor who lives in Kansas City, Missouri. She is a former investigative reporter with more than 25 years of experience as a journalist and writer ...

A new study linking tattoo ink to cancer risk has sparked concern worldwide. Scientists say the findings are worth watching, ...